Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Spirogen sold to AstraZeneca

16 October 2013

AstraZeneca to pay $440m for UK biotech business
Pharmaceutical group makes acquisition in oncology group spun out of university
Read: Guardian

AstraZeneca Buys Spirogen for $440 Million
MedImmune Unit Also Enters Deal with ADC Therapeutics
Read: Wall Street Journal